Just read that Chas McKhann joined Exagen's board back in mid-2025. Guy has an interesting track record - led Silk Road Medical and Apollo Endosurgery before they got acquired by Boston Scientific, both solid exits. Now he's on the board of this autoimmune diagnostics company that's trying to make waves in the testing space.

The thing is, McKhann brings like 25+ years in life sciences leadership, so it's not a random pick. Their CEO was pretty enthusiastic about it, talking about how his commercial expertise will help drive growth. Exagen's whole thing is their AVISE CTD test for diagnosing complex autoimmune stuff - lupus, rheumatoid arthritis, that kind of thing.

Seems like a smart move to get someone with proven execution experience on the board, especially in medtech where you need to navigate reimbursement and regulatory stuff. McKhann's got the Stanford MBA background too. Curious to see if this helps Exagen accelerate their commercialization strategy. The company's been pushing hard on the autoimmune diagnostics angle for a while now.